跳至主要内容
临床试验/NCT01297413
NCT01297413已完成1 期

A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Ischemic Stroke

Stemedica Cell Technologies, Inc.6 个研究点 分布在 1 个国家目标入组 38 人开始时间: 2011年2月最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
38
试验地点
6
主要终点
The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period.

研究概览

简要总结

The purpose of this study is to assess the safety and tolerability of allogeneic adult mesenchymal bone marrow cells administered intravenously to patients with ischemic stroke.

详细描述

Stroke remains a major global healthcare problem. Recent data compiled by the American Heart Association (AHA) for 2008 show that the annual incidence of new or recurrent stroke in the United States is about 780,000, with approximately 600,000 of these strokes being first attacks. Among adults age 20 and older, the estimated prevalence of stroke in 2005 was 5.8 million in the United States, resulting in >150,000 deaths annually, with 4.8 million stroke survivors alive today. Stroke ranks as the country's third leading cause of death, behind only cancer and heart disease. The only approved treatments of acute ischemic stroke involve restoring blood flow to the affected region by using thrombolytics or mechanical devices that physically remove clots. However, the use of thrombolytics is limited due to the therapeutic window of < 3-6 hours post onset of stroke symptoms such that only a small fraction of stroke patients receive this therapy. Following the completion of a stroke, there is little therapy to offer patients to promote recovery other than physical, occupational, and speech therapy.

Allogeneic mesenchymal stem cells have been used in a number of clinical trials for different indications demonstrated the safety of allogeneic mesenchymal stem cell treatment. In addition to their ability to differentiate into multiple different cell types that would be contributory to the recovery and repair of the brain by replacing destroyed cells, mesenchymal stem cells also secrete angiogenins, cytokines and trophic factors that can support and stimulate multiple other cell types. The cascade of cellular events following the release of these cytokines and trophic factors would also potentially lead to beneficial effects by restoring blood supply, by rescuing cells at risk, and by stimulating the remaining cell populations to repair and propagate new cells and synaptic connections.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of ischemic stroke for longer than 6 months
  • Brain CT/MRI scan at initial diagnosis and at enrollment consistent with ischemic stroke
  • No substantial improvement in neurologic or functional deficits for the 2 months prior to enrollment
  • NIHSS score between 6-20
  • Life expectancy greater than 12 months
  • Prior to treatment patient received standard medical care for the secondary prevention of ischemic stroke
  • Adequate organ function as defined by the following criteria:

排除标准

  • History of uncontrolled seizure disorder
  • History of cancer within the past 5 years.
  • History of cerebral neoplasm
  • Positive for hepatitis B, C or HIV
  • Myocardial infarction withing six months of study entry
  • Findings on baseline CT suggestive of subarachnoid or intracerebral hemorrhage within past 12 months.
  • Allergies to Bovine or Porcine products

研究组 & 干预措施

Stem cells

Experimental

All subjects will receive allogeneic adult mesenchymal bone marrow stem cells

干预措施: Allogeneic adult mesenchymal bone marrow stem cells (Biological)

结局指标

主要结局

The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period.

时间窗: 12 month

The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period as determined by the incidence and severity of adverse events, clinically-significant changes on clinical laboratory tests, vital signs, physical and neurologic examinations.

次要结局

  • National Institutes of Health Stroke Scale Score.(12 months)
  • The Geriatric Depression Scale Score.(12 month)
  • Mini Mental Status Exam score.(12 month)
  • Barthel Index Score.(12 month)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验